

The prospective data collection initiative on on small bowel, colorectal and anal cancer - a prospective observational cohort study.

Published: 06-02-2014

Last updated: 07-06-2025

The main objectives of this project are:- To start a prospective observational cohort study of patients who have been diagnosed with CRC, small bowel and anal cancer and follow them from time of diagnosis until death.- To prospectively collect data...

Ethical review	Approved WMO
Status	Recruitment started
Health condition type	Gastrointestinal neoplasms malignant and unspecified
Study type	Observational non invasive

Summary

ID

NL-OMON54603

Source

ToetsingOnline

Brief title

PLCRC

Condition

- Gastrointestinal neoplasms malignant and unspecified

Synonym

anal cancer Colorectal Cancer small bowel cancer

Research involving

Human

Sponsors and support

Primary sponsor: Dutch Colorectal Cancer Group

Source(s) of monetary or material Support: PGDX, Servier, Pierre Fabre, KWF, Dutch Colorectal Cancer Group, Stichting voor Lever- en Maag-Darm Onderzoek, Nutricia, Hoffmann-La Roche, Bayer, Eli Lilly

Intervention

- Other intervention

Keyword: Anal cancer, Cohort, Colorectal cancer, Prospective

Explanation

N.a.

Outcome measures

Primary outcome

1. Clinical parameters: medical history, co-morbidity, medication use, basic physical examination, laboratory results, imaging results, pathology results, tumor characteristics, treatment, treatment outcomes, hospital stays, interventions and adverse events.
2. Clinical endpoints: treatment effect, adenoma-free survival, disease-free survival, progression-free survival, overall survival and grade 3/4 (serious) adverse events.
3. Patient reported outcomes: health related quality of life, work participation and work ability.
4. Biobanking of blood and tumor tissue

Secondary outcome

nvt

Study description

Background summary

Survival after cancer diagnosis strongly depends on local tumor extent, lymph node involvement and the presence of distant metastases. However, there remains great inter-patient variability regarding treatment outcome. A combination of biochemical factors, histopathological features, genomic profile, environmental factors and other clinical factors are likely to influence prognosis and treatment effect, independent from tumor stage, but it is still unclear which, how, and to what extent these factors can influence tumor recurrence and

mortality in both early stage (I-III) and late stage (IV) colorectal cancer (CRC), small bowel cancer and anal cancer.

Although the results from prospective clinical trials will remain the backbone of evidence-based medicine, this concerns a highly selected patient population since the large majority (85%-95%) of cancer patients do not participate to clinical trials for various reasons. It is unlikely that trial participation will significantly improve in the near future. This fact has the following implications: 1) It is highly desirable to validate the results from trials in the general patient population. However, this is complicated by the fact that the documentation of patients treated in general practice (i.e. outside the scope of clinical trials) is largely insufficient to provide comparable patient cohorts in terms of prognostic characteristics and treatment parameters. 2) There is an increased availability of novel technologies that provide molecular markers with potential prognostic and/or predictive value. To test the clinical value of these markers large numbers of patients are required which greatly exceeds the number of patients who consent to participate to prospective clinical trials. 3) as a result of rapid technical developments, a range of new minimally invasive treatment options are entering the market. These interventions have the potential to be of great benefit to patients in terms of improved local control, higher probability of complete tumor removal, less damage to surrounding tissue, faster recovery and less short and long term side effects. Still, the interventions will have to prove their effectiveness, safety and superiority (or non inferiority) to standard cancer treatments on a patient level.

A prospective observational cohort study has the great opportunity to fill this gap.

We here propose to initiate such a study in patients with CRC, small bowel cancer and anal cancer in the Netherlands. If successful, it is expected that this study will be adopted to other tumor types as well..

Study objective

The main objectives of this project are:

- To start a prospective observational cohort study of patients who have been diagnosed with CRC, small bowel and anal cancer and follow them from time of diagnosis until death.
- To prospectively collect data on medical history, serious comorbidities, basic physical examination, imaging results, pathology results, tumor characteristics, treatment, treatment outcomes, hospital stays, interventions and adverse events.
- To store tumor tissue material, obtained during routine practice, for future research and to collect and store blood samples for observational and future research.

- To provide more accurate data on the treatment and clinical/ patient reported outcomes of CRC, small bowel and anal cancer in normal daily clinical care. To create a continuous basis for a large variety of research purposes including:

- A. Prognostic and predictive research
- B. Biological research and (epi)genetic research
- C. Studies that compare new therapies in a target population according to the Trials within Cohorts (TwICs) design.
- D. Health care policies and cost-effectiveness studies

Study design

prospective observational cohort study

Intervention

nvt

Study burden and risks

Since this is an observational study there are no additional risks associated with participation. Clinical (outcome) parameters will be collected during routine care and derived from medical charts. Consenting patients will be asked to fill out standard questionnaires.

If a patient gives informed consent to be approached for possible future studies within this project, he/she can be invited to participate in one or more studies within this project. Patients who consent to participate in the TwICs part of the project will be informed that their data will be used for comparative evaluation of safety and effectiveness of new interventions. They are also informed about the possibility that they may be offered an experimental intervention, which they may refuse. They are also informed about the fact that if they are not selected for a certain experimental intervention, and therefore are part of the control arm, they may be (temporarily) ineligible for some future experimental interventions.

In any instance, patients will never be withheld from standard, evidence-based treatments.

Contacts

Scientific

Universitair Medisch Centrum Utrecht
A.J.S. van Tetering
Heidelberglaan 100
Utrecht 3584 CX

Netherlands

0646919566

Public

Universitair Medisch Centrum Utrecht

A.J.S. van Tetering

Heidelberglaan 100

Utrecht 3584 CX

Netherlands

0646919566

Trial sites

Trial sites in the Netherlands

Rivierenland Ziekenhuis

Target size: 114

Universitair Medisch Centrum Utrecht

Target size: 116

Amsterdam UMC

Target size: 111

Elisabeth-Tweesteden ziekenhuis

Target size: 350

Ikazia Ziekenhuis

Target size: 150

Fransiscus Gasthuis & Vlietland

Target size: 300

Scheper Ziekenhuis

Target size: 140

OLVG

Target size: 350

Catharina-ziekenhuis

Target size: 200

Haaglanden Medisch Centrum

Target size: 150

Antonius Ziekenhuis

Target size: 150

Amphia Ziekenhuis

Target size: 300

Admiraal de Ruyter Ziekenhuis

Target size: 225

St. Jans Gasthuis	
Target size:	75
Universitair Medisch Centrum Groningen	
Target size:	120
MC Groep	
Target size:	75
Groene Hart Ziekenhuis	
Target size:	150
Alrijne Ziekenhuis	
Target size:	175
Sint Annaziekenhuis	
Target size:	100
Rivas Zorggroep	
Target size:	100
Gelre Ziekenhuizen	
Target size:	250
De Heel - Zaans Medisch Centrum	
Target size:	300
Diakonessenhuis Utrecht	
Target size:	114
Deventer Ziekenhuis	
Target size:	200
Zuyderland	
Target size:	250
Flevoziekenhuis	
Target size:	400
Spaarne Gasthuis	
Target size:	350
IJssellandziekenhuis	
Target size:	200
Bethesda Ziekenhuis	
Target size:	100
Refaja Ziekenhuis	
Target size:	100
Isala	
Target size:	300
Maastricht Universitair Medisch Centrum +	
Target size:	200
Saxenburgh groep	

Target size:	100
NKI-AVL	
Target size:	50
Maasstadziekenhuis	
Target size:	150
Rode Kruis Ziekenhuis	
Target size:	125
Reinier de Graaf Groep	
Target size:	200
Ziekenhuisgroep Twente	
Target size:	300
HagaZiekenhuis	
Target size:	200
Medisch Spectrum Twente	
Target size:	275
Noordwest Ziekenhuisgroep	
Target size:	325
Vrije Universiteit Medisch Centrum	
Target size:	50
Bravis Ziekenhuis	
Target size:	100
Dijklander Ziekenhuis	
Target size:	200
Martini Ziekenhuis	
Target size:	350
Elkerliek Ziekenhuis	
Target size:	100
Canisius Wilhelmina Ziekenhuis	
Target size:	200
Ziekenhuis Amstelland	
Target size:	250
Slingeland Ziekenhuis	
Target size:	300
Maasziekenhuis	
Target size:	300
Ziekenhuis Tjongerschans	
Target size:	300
St. Antonius Ziekenhuis	
Target size:	114

Meander Medisch Centrum	
Target size:	114
Zuwe Hofpoortziekenhuis Woerden	
Target size:	114
Tergooi ziekenhuizen	
Target size:	114
Erasmus Medisch Centrum	
Target size:	75
Leids Universitair Medisch Centrum	
Target size:	120
Radboud Universitair Medisch Centrum	
Target size:	100
Albert Schweitzer Ziekenhuis	
Target size:	275
MAASTRO clinic	
Target size:	250
Bernhoven	
Target size:	200
Medisch Centrum Leeuwarden (MCL)	
Target size:	250
Viecuri Medisch Centrum voor Noord-Limburg	
Target size:	250
Wilhelmina Ziekenhuis	
Target size:	125
Rijnstate Ziekenhuis	
Target size:	250
Zorgsaam ziekenhuis	
Target size:	100
Laurentius ziekenhuis	
Target size:	100
Jeroen Bosch Ziekenhuis	
Target size:	200
Maxima Medisch Centrum	
Target size:	175
Van Weel-Bethesda Ziekenhuis	
Target size:	90
Ziekenhuis St Jansdal	
Target size:	125
Medisch Centrum de Veluwe	

Target size:	50
Ziekenhuisvoorzieningen Gelderse Vallei	
Target size:	225
Sint Annaziekenhuis	
Target size:	300
Nij Smellinghe Ziekenhuis	
Target size:	500

Listed location countries

Netherlands

Eligibility criteria

Age

Adults (18-64 years)

Elderly (65 years and older)

Inclusion criteria

Age of 18 years or older

Histological proof of colorectal, small bowel or anal cancer, or a strong suspicion after imaging

Informed consent for longitudinal observational data collection

Exclusion criteria

Mentally incompetent

Study design

Design

Study phase:	N/A
Study type:	Observational non invasive
Intervention model:	Single
Allocation:	Non controlled trial

Masking:	Open (masking not used)
Control:	Uncontrolled
Primary purpose:	Other

Recruitment

NL	
Recruitment status:	Recruitment started
Start date (anticipated):	08-07-2014
Enrollment:	100000
Duration:	60 months (per patient)
Type:	Actual

Medical products/devices used

Product type:	N.a.
---------------	------

IPD sharing statement

Plan to share IPD: Undecided

Plan description

N.a.

Ethics review

Approved WMO	
Date:	18-06-2014
Application type:	First submission
Review commission:	METC NedMec
Approved WMO	
Date:	27-10-2014
Application type:	Amendment
Review commission:	METC NedMec
Approved WMO	
Date:	20-04-2015
Application type:	Amendment
Review commission:	METC NedMec
Approved WMO	

Date:	21-04-2015
Application type:	Amendment
Review commission:	METC NedMec
Approved WMO	
Date:	04-06-2015
Application type:	Amendment
Review commission:	METC NedMec
Approved WMO	
Date:	05-08-2015
Application type:	Amendment
Review commission:	METC NedMec
Approved WMO	
Date:	17-08-2015
Application type:	Amendment
Review commission:	METC NedMec
Approved WMO	
Date:	19-08-2015
Application type:	Amendment
Review commission:	METC NedMec
Approved WMO	
Date:	19-10-2015
Application type:	Amendment
Review commission:	METC NedMec
Approved WMO	
Date:	02-12-2015
Application type:	Amendment
Review commission:	METC NedMec
Approved WMO	
Date:	28-01-2016
Application type:	Amendment
Review commission:	METC NedMec
Approved WMO	
Date:	10-03-2016
Application type:	Amendment
Review commission:	METC NedMec
Approved WMO	

Date:	23-03-2016
Application type:	Amendment
Review commission:	METC NedMec
Approved WMO	
Date:	18-04-2016
Application type:	Amendment
Review commission:	METC NedMec
Approved WMO	
Date:	29-07-2016
Application type:	Amendment
Review commission:	METC NedMec
Approved WMO	
Date:	07-09-2016
Application type:	Amendment
Review commission:	METC NedMec
Approved WMO	
Date:	16-09-2016
Application type:	Amendment
Review commission:	METC NedMec
Approved WMO	
Date:	21-09-2016
Application type:	Amendment
Review commission:	METC NedMec
Approved WMO	
Date:	05-10-2016
Application type:	Amendment
Review commission:	METC NedMec
Approved WMO	
Date:	12-10-2016
Application type:	Amendment
Review commission:	METC NedMec
Approved WMO	
Date:	19-10-2016
Application type:	Amendment
Review commission:	METC NedMec
Approved WMO	

Date:	26-10-2016
Application type:	Amendment
Review commission:	METC NedMec
Approved WMO	
Date:	09-11-2016
Application type:	Amendment
Review commission:	METC NedMec
Approved WMO	
Date:	30-11-2016
Application type:	Amendment
Review commission:	METC NedMec
Approved WMO	
Date:	07-12-2016
Application type:	Amendment
Review commission:	METC NedMec
Approved WMO	
Date:	20-12-2016
Application type:	Amendment
Review commission:	METC NedMec
Approved WMO	
Date:	06-02-2017
Application type:	Amendment
Review commission:	METC NedMec
Approved WMO	
Date:	09-03-2017
Application type:	Amendment
Review commission:	METC NedMec
Approved WMO	
Date:	29-03-2017
Application type:	Amendment
Review commission:	METC NedMec
Approved WMO	
Date:	30-03-2017
Application type:	Amendment
Review commission:	METC NedMec
Approved WMO	

Date:	03-04-2017
Application type:	Amendment
Review commission:	METC NedMec
Approved WMO	
Date:	05-04-2017
Application type:	Amendment
Review commission:	METC NedMec
Approved WMO	
Date:	13-04-2017
Application type:	Amendment
Review commission:	METC NedMec
Approved WMO	
Date:	19-04-2017
Application type:	Amendment
Review commission:	METC NedMec
Approved WMO	
Date:	25-04-2017
Application type:	Amendment
Review commission:	METC NedMec
Approved WMO	
Date:	26-04-2017
Application type:	Amendment
Review commission:	METC NedMec
Approved WMO	
Date:	17-05-2017
Application type:	Amendment
Review commission:	METC NedMec
Approved WMO	
Date:	03-07-2017
Application type:	Amendment
Review commission:	METC NedMec
Approved WMO	
Date:	26-07-2017
Application type:	Amendment
Review commission:	METC NedMec
Approved WMO	

Date:	01-08-2017
Application type:	Amendment
Review commission:	METC NedMec
Approved WMO	
Date:	21-08-2017
Application type:	Amendment
Review commission:	METC NedMec
Approved WMO	
Date:	30-08-2017
Application type:	Amendment
Review commission:	METC NedMec
Approved WMO	
Date:	20-09-2017
Application type:	Amendment
Review commission:	METC NedMec
Approved WMO	
Date:	04-10-2017
Application type:	Amendment
Review commission:	METC NedMec
Approved WMO	
Date:	25-10-2017
Application type:	Amendment
Review commission:	METC NedMec
Approved WMO	
Date:	15-11-2017
Application type:	Amendment
Review commission:	METC NedMec
Approved WMO	
Date:	16-11-2017
Application type:	Amendment
Review commission:	METC NedMec
Approved WMO	
Date:	22-11-2017
Application type:	Amendment
Review commission:	METC NedMec
Approved WMO	

Date:	17-01-2018
Application type:	Amendment
Review commission:	METC NedMec
Approved WMO	
Date:	24-01-2018
Application type:	Amendment
Review commission:	METC NedMec
Approved WMO	
Date:	01-02-2018
Application type:	Amendment
Review commission:	METC NedMec
Approved WMO	
Date:	06-03-2018
Application type:	Amendment
Review commission:	METC NedMec
Approved WMO	
Date:	22-03-2018
Application type:	Amendment
Review commission:	METC NedMec
Approved WMO	
Date:	27-03-2018
Application type:	Amendment
Review commission:	METC NedMec
Approved WMO	
Date:	17-04-2018
Application type:	Amendment
Review commission:	METC NedMec
Approved WMO	
Date:	03-05-2018
Application type:	Amendment
Review commission:	METC NedMec
Approved WMO	
Date:	18-07-2018
Application type:	Amendment
Review commission:	METC NedMec
Approved WMO	

Date:	22-08-2018
Application type:	Amendment
Review commission:	METC NedMec
Approved WMO	
Date:	10-10-2018
Application type:	Amendment
Review commission:	METC NedMec
Approved WMO	
Date:	17-10-2018
Application type:	Amendment
Review commission:	METC NedMec
Approved WMO	
Date:	23-10-2018
Application type:	Amendment
Review commission:	METC NedMec
Approved WMO	
Date:	30-10-2018
Application type:	Amendment
Review commission:	METC NedMec
Approved WMO	
Date:	20-02-2019
Application type:	Amendment
Review commission:	METC NedMec
Approved WMO	
Date:	21-02-2019
Application type:	Amendment
Review commission:	METC NedMec
Approved WMO	
Date:	18-04-2019
Application type:	Amendment
Review commission:	METC NedMec
Approved WMO	
Date:	29-05-2019
Application type:	Amendment
Review commission:	METC NedMec
Approved WMO	

Date:	20-06-2019
Application type:	Amendment
Review commission:	METC NedMec
Approved WMO	
Date:	03-07-2019
Application type:	Amendment
Review commission:	METC NedMec
Approved WMO	
Date:	24-07-2019
Application type:	Amendment
Review commission:	METC NedMec
Approved WMO	
Date:	31-07-2019
Application type:	Amendment
Review commission:	METC NedMec
Approved WMO	
Date:	24-12-2019
Application type:	Amendment
Review commission:	METC NedMec
Approved WMO	
Date:	08-01-2020
Application type:	Amendment
Review commission:	METC NedMec
Approved WMO	
Date:	29-01-2020
Application type:	Amendment
Review commission:	METC NedMec
Approved WMO	
Date:	26-02-2020
Application type:	Amendment
Review commission:	METC NedMec
Approved WMO	
Date:	04-03-2020
Application type:	Amendment
Review commission:	METC NedMec
Approved WMO	

Date:	10-04-2020
Application type:	Amendment
Review commission:	METC NedMec
Approved WMO	
Date:	03-12-2020
Application type:	Amendment
Review commission:	METC NedMec
Approved WMO	
Date:	31-12-2020
Application type:	Amendment
Review commission:	METC NedMec
Approved WMO	
Date:	09-02-2021
Application type:	Amendment
Review commission:	METC NedMec
Approved WMO	
Date:	12-05-2021
Application type:	Amendment
Review commission:	METC NedMec
Approved WMO	
Date:	27-05-2021
Application type:	Amendment
Review commission:	METC NedMec
Approved WMO	
Date:	01-06-2021
Application type:	Amendment
Review commission:	METC NedMec
Approved WMO	
Date:	16-09-2021
Application type:	Amendment
Review commission:	METC NedMec
Approved WMO	
Date:	29-09-2021
Application type:	Amendment
Review commission:	METC NedMec
Approved WMO	

Date:	04-11-2021
Application type:	Amendment
Review commission:	METC NedMec
Approved WMO	
Date:	10-11-2021
Application type:	Amendment
Review commission:	METC NedMec
Approved WMO	
Date:	01-02-2022
Application type:	Amendment
Review commission:	METC NedMec
Approved WMO	
Date:	22-02-2022
Application type:	Amendment
Review commission:	METC NedMec
Approved WMO	
Date:	08-03-2022
Application type:	Amendment
Review commission:	METC NedMec
Approved WMO	
Date:	10-06-2022
Application type:	Amendment
Review commission:	METC NedMec
Approved WMO	
Date:	25-10-2022
Application type:	Amendment
Review commission:	METC NedMec
Approved WMO	
Date:	17-01-2023
Application type:	Amendment
Review commission:	METC NedMec
Approved WMO	
Date:	15-02-2023
Application type:	Amendment
Review commission:	METC NedMec
Approved WMO	

Date:	09-03-2023
Application type:	Amendment
Review commission:	METC NedMec
Approved WMO	
Date:	04-04-2023
Application type:	Amendment
Review commission:	METC NedMec
Approved WMO	
Date:	25-05-2023
Application type:	Amendment
Review commission:	METC NedMec
Approved WMO	
Date:	29-06-2023
Application type:	Amendment
Review commission:	METC NedMec
Approved WMO	
Date:	19-09-2023
Application type:	Amendment
Review commission:	METC NedMec
Approved WMO	
Date:	05-12-2023
Application type:	Amendment
Review commission:	METC NedMec
Approved WMO	
Date:	19-03-2024
Application type:	Amendment
Review commission:	METC NedMec
Approved WMO	
Date:	30-04-2024
Application type:	Amendment
Review commission:	METC NedMec
Approved WMO	
Date:	03-09-2024
Application type:	Amendment
Review commission:	METC NedMec
Approved WMO	

Date: 01-04-2025
Application type: Amendment
Review commission: METC NedMec

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register	ID
ClinicalTrials.gov	12-510
CCMO	NL47888.041.14
Research portal	NL-008405